What's Happening?
Since 2024, the U.S. Food and Drug Administration (FDA) has cleared the first over-the-counter (OTC) continuous glucose monitors (CGMs), making them available without a prescription. This development significantly broadens access to glucose monitoring
technology beyond individuals with diagnosed diabetes. Previously, CGMs were primarily used by people with diabetes, often requiring a prescription. Now, devices like Dexcom Stelo and Abbott Lingo are available for purchase by adults aged 18 and over, including those with type 2 diabetes not on insulin and adults without diabetes seeking general health insights. These wearable sensors, typically placed on the upper arm or abdomen, measure glucose levels in interstitial fluid and transmit real-time data to a paired app. While there is a 10-15 minute lag compared to fingerstick tests, CGMs provide continuous readings every 1-15 minutes, offering insights into how diet, exercise, and other factors affect glucose levels. This shift allows for greater personal health management and data-driven lifestyle adjustments.
Why It's Important?
The availability of OTC CGMs marks a pivotal shift in personal health management in the U.S., moving glucose monitoring from a clinical tool primarily for diabetes treatment to a broader wellness and preventative health device. This expansion is crucial for individuals with prediabetes or those focused on metabolic health and weight management, as it provides actionable data to understand their body's response to daily habits. For the healthcare industry, it signifies a growing trend towards consumer-driven health technology and personalized medicine. The market for Realtime Continuous Glucose Monitors is projected to grow significantly, with a Compound Annual Growth Rate (CAGR) of 13.6% from 2026 to 2033, driven by expanded indications and advanced algorithms. This growth will benefit manufacturers like Abbott and Dexcom, while also creating new opportunities for health coaches and digital health platforms that integrate CGM data. However, it also necessitates clear guidelines for health coaches to ensure responsible use and to differentiate between general wellness insights and medical advice, especially given that OTC device accuracy for non-diabetic users has not been validated with the same rigor as for diabetic populations.
What's Next?
The market for continuous glucose monitors is expected to see continued innovation and expansion. Future developments will likely include longer wear durations for sensors, smaller insertion profiles, and factory-calibrated sensors that eliminate the need for fingerstick calibration. The integration of advanced algorithms and artificial intelligence will enhance predictive capabilities, offering smart alerts for impending glucose events and reducing alarm fatigue. Cost reduction through lower manufacturing prices and expanded reimbursement coverage, including by public health programs and private insurers, will further drive adoption. The rise of closed-loop systems, where CGMs communicate directly with insulin pumps, will also push CGM adoption as a foundational component of artificial pancreas systems. Additionally, research into non-invasive glucose monitoring technologies, such as optical sensors and smart rings, is ongoing, though these still face significant regulatory hurdles and accuracy challenges compared to current approved CGMs. Health coaches will increasingly need to be knowledgeable about CGM technology to support clients effectively, focusing on educating about trends, connecting data to behavior, and building better questions for care teams, while adhering to scope boundaries.
Beyond the Headlines
The widespread availability of OTC CGMs raises deeper implications regarding data privacy, the potential for health anxiety, and the evolving role of health professionals. As more individuals track their glucose levels, the sheer volume of personal health data generated will necessitate robust data security and privacy protocols. There's also a risk that continuous monitoring could lead to increased anxiety or rigid food rules, particularly for individuals with a history of disordered eating, if not managed with careful guidance. Health coaches and other wellness providers will play a critical role in helping users interpret data responsibly, focusing on long-term trends rather than single readings, and avoiding the labeling of foods as 'good' or 'bad.' This shift also highlights the growing consumerization of health, where individuals are empowered with more data but require education to use it effectively. The ethical considerations of using medical-grade technology for general wellness, and the need for clear distinctions between medical diagnosis/treatment and lifestyle coaching, will become increasingly important as these devices become more commonplace.
